Berlin, Germany

Gastroenterologie am Bayerischen Platz

Adenoma

Intestinal Diseases

Non-alcoholic Fatty Liver Disease

Fibrosis

Crohn Disease

Inflammatory Bowel Diseases

Polyps

Fatty Liver

PICOPREP

Lanifibranor

Universitätsklinikum Hamburg-Eppendorf

Ferring

Inventiva Pharma

Pfizer

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

Gastroenterologie am Bayerischen Platz | Berlin, Germany

Site insights

Work at this site?

Active trials

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

Trial sponsors